Prospects for CAR T cell immunotherapy in autoimmune diseases: clues from Lupus.
B cell depletion
Systemic lupus erythematosus
cellular immunotherapy
chimeric antigen receptors
mouse models of autoimmune disease
Journal
Expert opinion on biological therapy
ISSN: 1744-7682
Titre abrégé: Expert Opin Biol Ther
Pays: England
ID NLM: 101125414
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
pubmed:
29
1
2022
medline:
7
4
2022
entrez:
28
1
2022
Statut:
ppublish
Résumé
Medicine stands at the threshold of a new era heralded by the vast potential of cell engineering. Like advances made possible by genetic engineering, current prospects for purposeful control of cell functions through cell engineering may bring breakthroughs in the treatment of previously intractable diseases. Engineering of cytotoxic T cells for expression of chimeric antigen receptors (CARs) instructs them to attack and destroy malignant cells and thus provides an exciting new approach in oncology. A decade of practical experience and first-in-human trials encourage the search for new and broader uses of CAR technology, including in autoimmune diseases. Systemic lupus erythematosus is an example of a broader category of autoimmune diseases, for which cell engineering will provide a powerful new therapeutic approach. This article describes different types of CAR T cell strategies that will provide new treatment options for patients with autoimmune diseases and replace conventional therapies.
Identifiants
pubmed: 35089116
doi: 10.1080/14712598.2022.2026921
doi:
Substances chimiques
Receptors, Antigen, T-Cell
0
Receptors, Chimeric Antigen
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM